A painful day for biotech investors (those long) in three graphs:
Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.
Leerink trimmed its price target on Gilead Sciences (GILD) stock today as it anticipates lower revenue from HIV sales in the future.